Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types

Hung Cheng Lai, Chien An Sun, Mu Hsien Yu, Huey Jung Chen, Hang Seng Liu, Tang Yuan Chu

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

To determine whether the status of human-papillomavirus (HPV) infection affects the clinical outcome of cervical carcinoma (CC), HPV genotype was prospectively determined in 94 consecutive CC cases subsequently followed for a median duration of 37.5 months. With a consensus PCR-RFLP method of HPV genotyping, 81 (86.2%) cancers were positive for HPV DNA. They were classified, according to the phylogenic similarities, into HPV-16-related (type 16, n = 45; type 31, n = 2), HPV-58-related (type 58, n = 17; type 33, n = 3; type 52, n = 2) and HPV-18-related (type 18, n = 8; type 68, n = 1) groups, and analyzed in relation to clinical outcome. The following results were observed: (i) Type-58-related HPVs were more prevalent in the old age (older than the median age of 52) group than in the young age group (41% vs. 14.6%, p = 0.045); (ii) 63% (5/8) of patients with advanced stages (III and IV) were HPV-negative, a figure much higher than that (9.3%, 8/84) of patients with early stages (stage I and II) (p = 0.002); (iii) the occurrence of adenocarcinoma or adenosquamous carcinoma was higher in the HPV-18-related group (50%) than in the HPV-16-related (33.3%) or the HPV-58-related (16.7%) groups (p = 0.024); (iv) the status of lymph-node metastasis and tumor grade did not correlate with HPV status; (v) 5-year survival rates were 90.2%, 80% and 74% for HPV-58-, HPV-16- and HPV-18-related groups, respectively (p = 0.03, after adjustment for tumor stage); (vi) in comparison with the HPV-16- related group, the relative risk of death in the HPV-58- and the HPV-18- related groups were 0.32 [95% CI, 0.07-1.49] and 1.87 [0.36-14.9] respectively. HPV genotype appears to affect the clinical behavior and outcome of cervical cancer. HPV-58-related types are prevalent in the older population, and appear to confer a favorable prognosis.

Original languageEnglish
Pages (from-to)553-557
Number of pages5
JournalInternational Journal of Cancer
Volume84
Issue number6
DOIs
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Papillomaviridae
Uterine Cervical Neoplasms
Human papillomavirus 18
Human papillomavirus 16
Age Groups
Genotype
Adenosquamous Carcinoma
Carcinoma
Neoplasms
Papillomavirus Infections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types. / Lai, Hung Cheng; Sun, Chien An; Yu, Mu Hsien; Chen, Huey Jung; Liu, Hang Seng; Chu, Tang Yuan.

In: International Journal of Cancer, Vol. 84, No. 6, 1999, p. 553-557.

Research output: Contribution to journalArticle

Lai, Hung Cheng ; Sun, Chien An ; Yu, Mu Hsien ; Chen, Huey Jung ; Liu, Hang Seng ; Chu, Tang Yuan. / Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types. In: International Journal of Cancer. 1999 ; Vol. 84, No. 6. pp. 553-557.
@article{f5a77146b6eb43dd8f6cebaf51b2c1cd,
title = "Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types",
abstract = "To determine whether the status of human-papillomavirus (HPV) infection affects the clinical outcome of cervical carcinoma (CC), HPV genotype was prospectively determined in 94 consecutive CC cases subsequently followed for a median duration of 37.5 months. With a consensus PCR-RFLP method of HPV genotyping, 81 (86.2{\%}) cancers were positive for HPV DNA. They were classified, according to the phylogenic similarities, into HPV-16-related (type 16, n = 45; type 31, n = 2), HPV-58-related (type 58, n = 17; type 33, n = 3; type 52, n = 2) and HPV-18-related (type 18, n = 8; type 68, n = 1) groups, and analyzed in relation to clinical outcome. The following results were observed: (i) Type-58-related HPVs were more prevalent in the old age (older than the median age of 52) group than in the young age group (41{\%} vs. 14.6{\%}, p = 0.045); (ii) 63{\%} (5/8) of patients with advanced stages (III and IV) were HPV-negative, a figure much higher than that (9.3{\%}, 8/84) of patients with early stages (stage I and II) (p = 0.002); (iii) the occurrence of adenocarcinoma or adenosquamous carcinoma was higher in the HPV-18-related group (50{\%}) than in the HPV-16-related (33.3{\%}) or the HPV-58-related (16.7{\%}) groups (p = 0.024); (iv) the status of lymph-node metastasis and tumor grade did not correlate with HPV status; (v) 5-year survival rates were 90.2{\%}, 80{\%} and 74{\%} for HPV-58-, HPV-16- and HPV-18-related groups, respectively (p = 0.03, after adjustment for tumor stage); (vi) in comparison with the HPV-16- related group, the relative risk of death in the HPV-58- and the HPV-18- related groups were 0.32 [95{\%} CI, 0.07-1.49] and 1.87 [0.36-14.9] respectively. HPV genotype appears to affect the clinical behavior and outcome of cervical cancer. HPV-58-related types are prevalent in the older population, and appear to confer a favorable prognosis.",
author = "Lai, {Hung Cheng} and Sun, {Chien An} and Yu, {Mu Hsien} and Chen, {Huey Jung} and Liu, {Hang Seng} and Chu, {Tang Yuan}",
year = "1999",
doi = "10.1002/(SICI)1097-0215(19991222)84:6<553::AID-IJC2>3.0.CO;2-4",
language = "English",
volume = "84",
pages = "553--557",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types

AU - Lai, Hung Cheng

AU - Sun, Chien An

AU - Yu, Mu Hsien

AU - Chen, Huey Jung

AU - Liu, Hang Seng

AU - Chu, Tang Yuan

PY - 1999

Y1 - 1999

N2 - To determine whether the status of human-papillomavirus (HPV) infection affects the clinical outcome of cervical carcinoma (CC), HPV genotype was prospectively determined in 94 consecutive CC cases subsequently followed for a median duration of 37.5 months. With a consensus PCR-RFLP method of HPV genotyping, 81 (86.2%) cancers were positive for HPV DNA. They were classified, according to the phylogenic similarities, into HPV-16-related (type 16, n = 45; type 31, n = 2), HPV-58-related (type 58, n = 17; type 33, n = 3; type 52, n = 2) and HPV-18-related (type 18, n = 8; type 68, n = 1) groups, and analyzed in relation to clinical outcome. The following results were observed: (i) Type-58-related HPVs were more prevalent in the old age (older than the median age of 52) group than in the young age group (41% vs. 14.6%, p = 0.045); (ii) 63% (5/8) of patients with advanced stages (III and IV) were HPV-negative, a figure much higher than that (9.3%, 8/84) of patients with early stages (stage I and II) (p = 0.002); (iii) the occurrence of adenocarcinoma or adenosquamous carcinoma was higher in the HPV-18-related group (50%) than in the HPV-16-related (33.3%) or the HPV-58-related (16.7%) groups (p = 0.024); (iv) the status of lymph-node metastasis and tumor grade did not correlate with HPV status; (v) 5-year survival rates were 90.2%, 80% and 74% for HPV-58-, HPV-16- and HPV-18-related groups, respectively (p = 0.03, after adjustment for tumor stage); (vi) in comparison with the HPV-16- related group, the relative risk of death in the HPV-58- and the HPV-18- related groups were 0.32 [95% CI, 0.07-1.49] and 1.87 [0.36-14.9] respectively. HPV genotype appears to affect the clinical behavior and outcome of cervical cancer. HPV-58-related types are prevalent in the older population, and appear to confer a favorable prognosis.

AB - To determine whether the status of human-papillomavirus (HPV) infection affects the clinical outcome of cervical carcinoma (CC), HPV genotype was prospectively determined in 94 consecutive CC cases subsequently followed for a median duration of 37.5 months. With a consensus PCR-RFLP method of HPV genotyping, 81 (86.2%) cancers were positive for HPV DNA. They were classified, according to the phylogenic similarities, into HPV-16-related (type 16, n = 45; type 31, n = 2), HPV-58-related (type 58, n = 17; type 33, n = 3; type 52, n = 2) and HPV-18-related (type 18, n = 8; type 68, n = 1) groups, and analyzed in relation to clinical outcome. The following results were observed: (i) Type-58-related HPVs were more prevalent in the old age (older than the median age of 52) group than in the young age group (41% vs. 14.6%, p = 0.045); (ii) 63% (5/8) of patients with advanced stages (III and IV) were HPV-negative, a figure much higher than that (9.3%, 8/84) of patients with early stages (stage I and II) (p = 0.002); (iii) the occurrence of adenocarcinoma or adenosquamous carcinoma was higher in the HPV-18-related group (50%) than in the HPV-16-related (33.3%) or the HPV-58-related (16.7%) groups (p = 0.024); (iv) the status of lymph-node metastasis and tumor grade did not correlate with HPV status; (v) 5-year survival rates were 90.2%, 80% and 74% for HPV-58-, HPV-16- and HPV-18-related groups, respectively (p = 0.03, after adjustment for tumor stage); (vi) in comparison with the HPV-16- related group, the relative risk of death in the HPV-58- and the HPV-18- related groups were 0.32 [95% CI, 0.07-1.49] and 1.87 [0.36-14.9] respectively. HPV genotype appears to affect the clinical behavior and outcome of cervical cancer. HPV-58-related types are prevalent in the older population, and appear to confer a favorable prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0032763165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032763165&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19991222)84:6<553::AID-IJC2>3.0.CO;2-4

DO - 10.1002/(SICI)1097-0215(19991222)84:6<553::AID-IJC2>3.0.CO;2-4

M3 - Article

VL - 84

SP - 553

EP - 557

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 6

ER -